ArticleJornal de pediatria2026
Global burden and inequalities of Hodgkin and non-Hodgkin lymphoma among children aged 0-14 years, 1990-2021: a GBD 2021 analysis with forecasts to 2035.
Article in Jornal de pediatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChildhood Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are potentially curable, but outcomes differ across development levels. The authors assessed global burden and inequalities among children aged 0-14 years from 1990 to 2021 and projected burden to 2035.
methodsGBD 2021 estimates for 204 locations provided age-standardized incidence, mortality, and disability-adjusted life-year (DALY) rates by sex and Sociodemographic Index (SDI). Estimated annual percentage changes (EAPCs) summarized trends; the slope index of inequality (SII) and concentration index (CII) measured absolute and relative inequalities. An exploratory Country Priority Index (CPI) combined mortality and DALY rates, absolute DALYs, and adverse trajectories. Autoregressive integrated moving average (ARIMA) models generated forecasts.
resultsFrom 1990 to 2021, incidence declined modestly. Mortality declined from 0.152 to 0.095 per 100,000 for HL and from 0.75 to 0.45 for NHL; corresponding DALY rates fell from 12.50 to 7.78 and from 63.38 to 37.83. Boys and low-SDI settings had higher burdens, and SDI was strongly inversely associated with mortality and DALYs. For NHL mortality, the SII improved from -0.91 to -0.61, whereas the CII worsened from -0.38 to -0.49. The CPI ranked Pakistan, Uganda, South Sudan, Zimbabwe, and Nigeria highest. By 2035, projected HL and NHL incidence rates were 0.20 and 0.98, mortality rates 0.08 and 0.35, and DALY rates 6.22 and 27.25 per 100,000, respectively.
conclusionChildhood lymphoma outcomes improved globally, but relative inequalities remained concentrated in lower-SDI settings. CPI-based prioritization supports investment in diagnosis, treatment, essential medicines, supportive care, and surveillance. Forecasts represent conditional baseline trajectories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.